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Take home message 
Telomere length, a marker of biological age, is decreased in asthma and COPD patients and 
positively associated with spirometric indices.
  
Abstract  
Several clinical studies suggest the involvement of premature aging processes in COPD. 
Using an epidemiological approach we studied whether accelerated aging indicated by 
telomere length, a marker of biological age, is associated with COPD and asthma, and 
whether intrinsic age-related processes contribute to the inter-individual variability of lung 
function. 
Our meta-analysis of 14 studies included 934 COPD cases with 15,846 controls defined 
according to GLI criteria (or 1,189 COPD cases according to GOLD), 2,834 asthma cases 
with 28,195 controls, and spirometric parameters (FEV1, FVC and FEV1/FVC) of 12,595 
individuals. Associations with telomere length were tested by linear regression, adjusting for 
age, sex, and smoking status.  
We observed negative associations between telomere length and asthma (β=-0.0452, p=0.024) 
as well as COPD (β=-0.0982, p=0.001), with associations being stronger and more significant 
when using GLI in comparison to GOLD. In both diseases, effects were stronger in women 
compared to men. The investigation of spirometric indices showed positive associations 
between telomere length and FEV1 (p=1.07x10-7), FVC (p=2.07x10-5), and their ratio 
FEV1/FVC (p=5.27x10-3). The effect was somewhat weaker in apparently healthy subjects 
compared to COPD or asthma patients. 
Our results provide indirect evidence for the hypothesis that cellular senescence may 
contribute to the pathogenesis of COPD and asthma and that lung function may reflect 
biological aging primarily due to intrinsic processes which are likely to be aggravated in lung 
diseases.  
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Introduction 
An increasing life expectancy is associated with an increased susceptibility for prevailing 
chronic diseases, such as cardiovascular and neurological diseases, type 2 diabetes and cancer, 
suggesting that common, age-related processes are involved in these diseases [1-4]. The lung 
is known to undergo age-related processes associated with a continuous decline in lung 
function  [5, 6]. Chronic obstructive pulmonary disease (COPD), lung cancer and idiopathic 
pulmonary fibrosis are lung diseases with an increase in incidence by age. In COPD, chronic 
inflammation and oxidative stress are among the generally accepted pathophysiological 
mechanisms but, as discussed for other degenerative diseases, accelerated aging resulting in 
premature cell senescence may contribute to the pathobiology [7-9]. Although clinical and 
epidemiological studies provide some evidence for this hypothesis the data base is still limited 
[8] so that our study aims to provide further clues on this. 
Telomeres made up of the simple repetitive sequence TTAGGG in humans [10] are 
specialized DNA structures which in concert with telomere specific proteins protect the ends 
of chromosomes and maintain the integrity of the genome [3]. They progressively shorten 
with each cell division [11] and after reaching a critical length, either cellular senescence or 
apoptosis is induced [3]. Telomeres are therefore considered as a marker of biological age. 
Their length is affected by various factors, such as chronic inflammation or oxidative stress 
[3], but has also been shown to have a heritable component [12]. Recent data suggest that 
shorter telomere length is associated with an increased risk of total and cancer mortality in 
COPD patients [13]. Shortened telomeres were found in pulmonary vascular endothelial cells, 
alveolar epithelial cells and circulating leukocytes of COPD patients [14-18] supporting the 
notion of accelerated aging in COPD. Rode et al. [18] reported multivariable-adjusted odds 
ratios of 1.15 (95% CI 1.06 to 1.25) for shortest versus longest telomere quartiles for COPD. 
Smoking, a major cause of COPD, is associated with different signs of premature aging which 
  
is particularly obvious in the skin [8] suggesting that environmental exposure may play an 
important role in triggering processes related to biological aging.  
Since the lung is continuously exposed to environmental hazards, lung function per se may be 
a surrogate marker for biological age in light of the large inter-individual variability observed 
[19]. Only a few case-control studies [14, 20] have investigated the relationship between 
telomere length and spirometric indices. One large population based study was recently 
published by Rode et al. [18] reporting a modest correlation between telomere length and lung 
function in terms of the spirometric indices forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC) and their ratio FEV1/FVC. 
In a meta-analysis of 14 European studies embedded in the ENGAGE consortium, we studied 
the relationship between telomere length, lung function and lung disease to address the 
question whether accelerated aging indicated by telomere length may be involved in the 
pathogenesis of COPD and asthma, and whether intrinsic age-related processes may 
contribute to the inter-individual variability of lung function. For this purpose, we explored 
the association between circulating leukocyte telomere length and COPD or asthma. Although 
these are different obstructive disease entities, they share chronic inflammation as a hallmark 
of disease which may result in accelerated aging and telomere shortening. We further 
investigated the association between telomere length and lung function using the spirometric 
indices FEV1, FVC and FEV1/FVC. 
 
 
Methods 
Study populations 
This meta-analysis comprises data from 14 European studies, with details provided in the 
Online Data Supplement. In the analysis of telomere length and COPD, we combined data 
  
of nine studies (EX-ATHLETES, FITSA, KORA Age, KORA F3, KORA F4, NAG-FIN, 
NFBC1966, TwinGene, and TwinsUK), totaling 934 cases and 15,846 controls (Table 1).  
COPD was defined as z(FEV1/FVC) < -1.6445 (5% lower limit of normal (LLN) according to 
the Global Lung Function Initiative (GLI) [19]) if spirometry was available (see below), or 
based on physician diagnosis otherwise. In a sensitivity analysis we replaced the GLI criteria 
by the GOLD criteria (FEV1/FVC<0.70) [21] to define COPD. The analysis of telomere 
length in asthma comprised 13 studies (ERF, EX-ATHLETES, FITSA, GRAPHIC, KORA 
Age, KORA F3, KORA F4, NAG-FIN, NFBC1966, NTR, QIMR, TwinGene, and TwinsUK), 
with  2,834 cases and 28,195 controls (Table 2). Asthma was defined by physician diagnosis 
or self-reports in questionnaires or by asthma-specific medication intake. Spirometric 
measurements (FEV1, FVC and FEV1/FVC) were available for 12,595 individuals from seven 
studies (FITSA, KORA Age, KORA F3, KORA F4, NFBC1966, TwinFat, and TwinsUK). 
Spirometry had been performed in line with international standards [22, 23]. Relative 
telomere length was determined by qPCR [24] in all studies. Measurement details by study 
are provided in the Online Data Supplement. The local ethic committees had approved all 
studies and all participants had given their written informed consent. 
 
Statistical analysis 
Associations of telomere length with COPD, asthma, FEV1, FVC and FEV1/FVC were tested 
by linear regression models with telomere length as outcome in all models. To account for 
heterogeneity between studies, telomere length was standardized within each study prior to 
the analysis, using a z-transformation after initially adjusting for age and sex, i.e. scaling the 
residuals of the regression of telomere length on age and sex to zero mean and unit variance. 
COPD and asthma cases, respectively, were coded "1", whereas controls were coded "0". 
Also the spirometric indices were transformed to z-scores taking into account age, height, and 
gender of each individual. Therefore Global Lung Function Initiative (GLI) reference 
  
equations for spirometry [19] were applied to calculate z-scores for FEV1, FVC, and 
FEV1/FVC from skewness (L), the coefficient of variation (S) and the predicted value (M) 
according to the LMS-equations by using the provided software 
(http://www.lungfunction.org/tools).   
Within the linear regression model we adjusted for ever and current smoking, as well as for 
study specific covariates as case/control status or family structure if appropriate. As both, 
telomere length and lung function measurements were already adjusted for age and sex, the 
association model itself did not contain these covariates. All analyses were primarily 
conducted in all available study samples and additionally conducted stratified by sex. The z-
transformation of telomere length was performed in males and females separately for the sex-
stratified analysis. For the analyses of FEV1, FVC, and FEV1/FVC, we additionally stratified 
into the subgroups “apparently lung healthy”, “COPD cases” and “asthmatics”. 
The group of apparently lung healthy subjects was determined by exclusion of all subjects 
with a history of asthma, COPD, or other reported respiratory diseases, and all subjects with a 
reported acute respiratory tract infections within the last three weeks. The group was further 
divided into “current/former” and “never” smokers. In the group of healthy smokers we 
further investigated subjects showing the lower and upper 25%-quantiles of lung function 
(FEV1, FVC or FEV1/FVC respectively). The single study results were combined in a meta-
analysis with inverse variance weighting, performed in the statistical software R 
(http://www.r-project.org) using the meta-package with fixed and random effects. As a 
measure for heterogeneity, I² values were calculated [25] and Cochran’s heterogeneity test 
was performed. As a sensitivity analysis in COPD, we excluded first all subjects over 70 
years and then all subjects over 60 years from the analysis. 
 
Results 
COPD 
  
By combining nine studies including 934 COPD cases and 15,846 controls according to GLI 
(Table 1), we observed a significant negative association between COPD and telomere length 
(β=-0.0982, p=0.001 with fixed effects; β=-0.0953, p=0.012 with random effects, I²=27.7%, 
phet=0.198). With COPD defined by GOLD criteria there were more COPD cases (n=1,189) 
with an increase in older and a reduction in younger individuals. On the other hand, the 
association with telomere length using GOLD criteria was more heterogeneous across studies 
and less significant (β=-0.0676, p=0.018 with fixed effects, β=-0.0629, p=0.117 with random 
effects; I²=42.3%, phet=0.085). Figure 1 shows study specific and combined effect estimates 
of a fixed and random effects model with COPD defined by GLI. The association was strong 
in the female subsample (n=10,435; β=-0.1306, p=3.6x10-4 with fixed effects; β=-0.1312, 
p=6.7x10-4 with random effects; I²=5.8%, phet=0.385)  whereas in the male subsample no 
significant relationship was detectable (n=6,345; β=-0.0242, p=0.663 with fixed effects; β=-
0.0329, p=0.622 with random effects; I²=23.5%, phet=0.250). Figure E1 shows the meta-
analysis stratified for sex. The two studies showing positive effect estimates, EX-ATHLETES 
and NAG-FIN, are selective in their study design: NAG-FIN comprises families of ever heavy 
smokers, and the EX-ATHLETES are former male top athletes with matched controls and a 
mean age of 72.7 years. Since COPD shows an age-related increase in incidence, we 
conducted sensitivity analyses to investigate whether the observed association is affected by 
age. Exclusion of subjects >70 years or >60 years showed no significant differences for the 
effect estimates in subgroups of both sexes (Figure E2), confirming that the association is not 
driven by older age groups.  
 
Asthma  
By combining 13 studies with 2,834 asthma cases and 28,195 controls (Table 2, Figure 2), 
we observed a negative association between telomere length and asthma. This was significant 
in a fixed effects model (β =-0.0452, p=0.024) and suggestive in a random effects model (β=-
  
0.0446, p=0.093; I²=30.4%, phet=0.140). The effect was driven by the female subsample 
(n=18,724, β=-0.0764, p=0.002 with fixed effects; β =-0.0809, p=0.005 with random effects; 
I²=15.8%, phet=0.289) and not seen in the male subsample (n=12,305; β=0.0182, p=0.594 with 
fixed effects; β=0.0139, p=0.771 with random effects; I²=40.3%, phet=0.080; Figure E3).   
 
Lung function  
By combining data of seven studies, totaling 12,595 individuals (Table 3, Figure 3), we 
observed highly significant positive associations between telomere length and spirometric 
indices measured as FEV1 (β=0.0455, p=1.07x10-7 with fixed and random effects; I²=0%), 
FVC (β=0.0401, p=2.07x10-5 with fixed and random effects; I²=0%), and their ratio 
FEV1/FVC (β=0.0238, p=5.27x10-3 with fixed and random effects; I²=0%). The effect for 
FEV1 was higher in women compared to men (β=0.0548 versus β=0.286 with random 
effects). The meta-analysis stratified by sex is shown in Figure E4. 
Figure 4 shows the association results stratified by lung health status. Compared to “healthy”, 
we found somewhat stronger effects in the disease subgroups of COPD and asthma cases. A 
comparison of the effect estimates stratified by health status as well as by sex is presented in 
Figure E5. The stronger effects found in COPD were predominantly seen in men and less 
obvious in women. The opposite was observed for asthma, where the effects were strong in 
women. With regard to smoking, within the healthy subgroups, the observed effects were 
stronger in “healthy never smokers” compared to “healthy ever smokers” for FEV1 and FVC 
(see Figure E6). To further explore the contribution of smoking we stratified the group of 
healthy smokers (current or ex) by lung function status (lower 25% or upper 25% within this 
subgroup). The results suggest that there was no difference between those two groups for 
FEV1. In FVC, an effect was only seen in individuals with poor lung function (lower 25%). 
Although differences between subgroups were noticeable, they did not differ significantly.  
  
 
 
Discussion 
We conducted a large study investigating the relationship between telomere length and lung 
function and disease, assessed in multiple European cohorts unselected for lung disease. We 
found highly significant positive associations between telomere length from peripheral 
leukocytes and spirometric indices measured as FEV1, FVC, and FEV1/FVC in a meta-
analysis of seven studies with 12,595 individuals. When stratifying by lung health status, 
larger effects were seen in the subgroups of COPD patients or asthmatics. This suggests that 
lung function decline in part reflects biological aging due to intrinsic processes which are 
likely to be aggravated in asthma or COPD due to mechanisms promoting cell senescence. 
 
Tobacco smoke is a well-known environmental factor which promotes aging processes and 
cellular senescence [8]. The recent large, population-based study by Rode et al. (2013) [18] 
revealed that having ever smoked and the cumulative pack-years smoked were associated 
with telomere length in 46,396 adults. This is in line with previous population-based findings 
[26]. However, in clinical studies these effects were not seen [14, 17, 20]. When stratifying by 
smoking status, we observed no evident associations between telomere length and lung 
function indices in ever smokers. Also stratifying by lung function within the group of healthy 
smokers (current and ex) did not clarify the issue, although for FVC an effect could be 
detected in smokers of the lower quartile. The underlying reason for detecting no effect may 
be found in the complex interactions between smoking and genetic and/or life style factors, 
such as antioxidant diet or physical activity, affecting biological age and its markers [1, 3, 27-
32], but also in the heterogeneity of smoking exposures, its amount and duration. 
 
  
Up to now, a limited number of studies have addressed the association between lung function 
and telomere length. Mui et al. (2009) [20] observed a positive association in a sample of 
COPD patients, and Tsuji et al. (2006) [16] reported that airflow limitation and alveolar cell 
senescence were positively correlated with each other. Other studies failed to find significant 
associations between spirometric parameters and telomere length [14, 17, 33], although one 
study found that parameters of gas exchange (arterial oxygen and carbon dioxide pressures) 
were associated with telomere length in COPD patients [14]. The large population-based 
study by Rode et al. (2013) found weak but statistical significant positive correlations 
between telomere length and spirometric indices, which is confirmed by our results. 
Furthermore we observed the effects to be somewhat stronger in COPD or asthma patients 
compared to healthy individuals, suggesting that intrinsic age-related processes may be 
aggravated by chronic inflammatory processes occurring either locally in the lung or 
systemically. 
 
In both, COPD and asthma patients, we observed shorter telomeres compared to healthy 
controls. In COPD, the association was stronger when defining cases by the age dependent 
lower limit of normal for FEV1/FVC according to GLI [19] compared to the fixed cut off 
given by GOLD [21]. This suggests that the GLI approach better suits the transition from 
health to disease. For COPD and asthma, effect estimates appeared to be larger in females 
than in males although sex differences were not statistically significant. With respect to 
COPD, this might be consistent with the observation that females appear to be more 
susceptible to COPD than males [34] but the causality certainly needs to be proved. Whereas 
our findings for asthma are novel, the results for COPD are in line with previous findings in 
case-control [14-17] and population-based studies [18].  This suggests that, as already shown 
for other chronic diseases [1, 3, 35], accelerated aging may contribute to the pathogenesis of 
asthma and COPD. 
  
 
Our epidemiological finding is supported by results from clinical studies showing shorter 
telomeres in alveolar epithelial and endothelial cells from patients with emphysema [16]. 
Amsellem et al. reported a higher percentage of pulmonary vascular endothelial cells stained 
for senescence markers in COPD patients than in lung healthy controls [15]. This in in line 
with senescent-type growth characteristics of lung fibroblasts [36]. Furthermore, cellular 
senescence of pulmonary smooth muscle cells appears to be involved in the pathogenesis of 
pulmonary hypertension in COPD [37]. Several mechanisms have been proposed for 
abnormal aging in COPD including chronic inflammation, oxidative stress, mitochondrial 
dysfunction, altered energy metabolism, abnormal regulation of aging processes, cellular and 
immunosenescence, and telomere dysfunction [3, 7-9, 15]. Analogous mechanisms in asthma 
have not been explored in detail but due to the inflammatory nature of both diseases some of 
the above mentioned factors are likely to also play a role in asthma. Possible consequences for 
both diseases are very difficult to predict but one might speculate that the aging processes 
may be reflected in the shorter life expectancy and an increased risk for cognitive impairment 
and dementia as reported for asthma and COPD [38-40]. 
 
The observed associations between telomere length and both diseases were not as strong as 
one might have initially expected, considering the large sample size included. In case of 
COPD, in the population-based approach of Rode et al. [18] also a much weaker association 
was observed than previous case-control studies had suggested [14]. In our case this may be 
related to the fact that mostly mild to moderate disease stages were included in the study 
samples. E.g. for COPD in the KORA cohorts GOLD stages I and II covered 94.3% of COPD 
cases. Rode et al. also observed weaker effects for stages I (OR=1.09, 95% CI 0.97 to 1.23) 
and II (OR=1.17, 1.04 to 1.31) compared to more advanced GOLD stages [18] after multiple 
  
adjustment. In the case of asthma, the weakness of association could be due to the different 
methods of ascertaining asthma cases or phenotypic heterogeneity. 
 
Moreover, as in many other studies, telomere length has been measured in circulating 
leucocytes and not in the cells of the primarily affected organ, i.e. the lung. Studies addressing 
the comparability of telomere length between different tissues found strong correlations in 
healthy individuals, but somewhat blunted ones in disease [41-44]. We cannot rule out that 
this may be a factor which affects the association of telomere length with lung diseases. 
Leukocyte telomere length is a complex trait that is shaped by many factors including genetic, 
epigenetic, lifestyle and environmental determinants, and their complex interaction is hardly 
understood. In the present analysis we therefore adjusted only for well accepted determinants. 
Certainly, the population-based epidemiological nature of the studies included comes along 
with distinct limitations. Population-based samples typically only scarcely include severe 
cases of lung diseases but predominantly early disease stages, in which age-related 
mechanisms may not be as significant as in more advanced stages that are primarily included 
in clinical cohorts [14-17]. Furthermore, our study design did not allow taking into account 
the known heterogeneity of COPD and asthma phenotypes. These entities may have different 
impacts on telomere length or may trigger premature aging processes via telomere-
independent mechanisms as reported for fibroblasts of patients with lung emphysema [45]. 
Unlike in clinical studies, diagnosis of COPD and asthma had to rely mainly on self-reported 
physician diagnosis which certainly adds some potential for misclassification error. On the 
other hand, we employed the recent GLI reference values [19] for COPD diagnosis wherever 
possible. Also confounding effects, such as smoking or medication, could not be accounted 
for in the same way as a matched case-control study design can. 
 
  
As this analysis combines a number of studies which are heterogeneous in their design (see 
Online Data Supplement), we report results of random effects models in addition to the 
results based on fixed effects in order to account for this heterogeneity. Naturally, confidence 
intervals are larger with random effects. While both models reach statistical significance in 
COPD, statistical significance was only reached with the fixed effects model for asthma. The 
observed effect point estimates, however, were comparable between the fixed and the random 
effects model, supporting the biological significance of our findings. In COPD, our sensitivity 
analysis did not show an age-dependency (Figure E2). Two studies showing positive effect 
estimates for COPD were selective in their study design; in case of the EX-ATHLETES the 
positive effect of life-time physical exercise on biological age may have played a role [3, 27, 
46, 47]. 
 
Conclusions 
We investigated the relationship of telomere length, as a marker of biological age, with lung 
function and respiratory disease. We found highly significant positive associations between 
telomere length and lung function. Furthermore, shorter telomeres were seen in patients with 
COPD and asthma cases compared to healthy controls. Our results provide indirect evidence 
for the hypothesis that premature aging is involved in the pathophysiology of COPD and 
asthma and that lung function partially reflects biological aging due to intrinsic processes. 
These processes are likely to be aggravated by lung diseases promoting cellular senescence, 
although the average effect seems to be not particularly strong. 
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Figure legends 
 
Figure 1: Associations between telomere length and COPD 
Forest Plot comparing effects between studies, and showing combined effects in a fixed 
effects model as well as in a random effects model. Sex-stratified results are based on random 
effects models. 95% confidence intervals are given for all estimates. COPD was defined by 
GLI criteria. 
 
Figure 2: Association between telomere length and asthma 
Forest Plot comparing effects between studies, and showing combined effects in a fixed 
effects model as well as in a random effects model. Sex-stratified results are based on random 
effects models. 95% confidence intervals are given for all estimates. 
  
 
 
Figure 3: Telomere length is associated with FEV1, FVC and (FEV1/FVC) 
Forest Plot comparing effects between studies, and showing combined effects in a fixed 
effects model as well as in a random effects model. Sex-stratified results are based on random 
effects models. 95% confidence intervals are given for all estimates. 
  
 
  
 
Figure 4: Associations between telomere length and FEV1, FVC and (FEV1/FVC), 
stratified by health status. 
Forest Plot showing effects in the overall sample as well as in “apparently lung healthy” 
individuals only, for asthmatics, and patients with COPD to test the impact of lung disease on 
the effect. Effects are based on random effects models. 95% confidence intervals are given for 
all estimates. 
 
 
 
  
Tables 
Table 1: Study characteristics of studies in COPD analysis defined by GLI criteria  
Study 
total 
sample 
size 
number of COPD 
cases
number of 
women 
Smoking status
never/former/current
Age [years]
mean (sd)
overall
Age [years]
mean (sd)  
in cases
Age [years] 
mean (sd) 
in controls 
Age 
diff 
EX-ATHLETES 577 43 (7.5%) 0 (0%) 361/177/39 72.68 (5.92) 74.63 (6.97) 72.52 (5.81) 2.11 
FITSA 386  22 (5.7%) 386 (100%) 333/31/21 68.45 (3.38) 69.27 (3.60) 68.40 (3.36) 0.87 
KORA Age 905  54 (6.0%) 451 (49.8%) 510/351/44 75.67 (6.34) 75.02 (6.28) 75.71 (6.35) -0.69 
KORA F3 875  36 (4.1%) 458 (52.3%) 377/260/238 44.45 (8.93) 44.11 (9.57) 44.46 (8.91) -0.35 
KORA F4 2,803  243 (8.7%) 1,480 (52.8%) 1,230/1,048/525 54.86 (12.84) 59.35 (12.73) 54.44 (12.77) 4.91 
NAG-FIN 1,718 126 (7.3%) 782 (45.5%) 204/804/710 55.89 (7.63) 58.40 (9.40) 55.69 (7.44) 2.71 
NFBC1966  4,984  147 (2.9%)  2,594 (52.0%) 2,479/592/1,913 31 (0.2) 31 (0.2) 31 (0.2) 0 
TwinGene 597 52 (8.7%) 597 (100%) 358/239* 71.72 (5.89) 72.50 (5.31) 71.65 (5.95) 0.85 
TwinsUK 3,935  211 (5.4%) 3,687 (93. 7%) 2,760/743/432 51.17 (13.12) 53.34 (13.06) 51.02 (13.14) 2.32 
total  16,780  934 (5.6%)  10,435 (62.2%)  1.71# 
*for TwinGene the numbers correspond to current smoking no/yes. #mean age difference between cases and controls, weighted by total sample size. 
Table 2: Study characteristics of studies in asthma analysis 
  
Study 
total 
sample 
size 
number of 
asthma cases
number of 
women 
Smoking status 
never/former/cur
rent
Age [years]
mean (sd)
overall
Age [years]
mean (sd)
in cases
Age [years]
mean (sd)
in controls Age diff  
ERF 2,580 41 (1.6%) 1,468 (56.9%) 981/691/908 49.80 (15.67) 51.14 (13.35) 49.78 (15.71) 1.36 
EX-ATHLETES 577 44 (7.6%) 0 (0%) 361/177/39 72.68 (5.92) 73.23 (5.98) 72.63 (5.92) 0.60 
FITSA 423 33 (7.8%) 423 (100%) 369/32/21 68.61 (3.41) 68.27 (3.48) 68.64 (3.41) -0.37 
GRAPHIC 2,007 76 (3.8%) 994 (49.5%) 1,109/491/407 39.31 (14.50) 37.09 (14.20) 39.38 (14.51) -2.29 
KORA Age 868 51 (5.9%) 435 (50.1%) 494/332/42 75.65 (6.34) 76.02 (6.10) 75.63 (6.36) 0.39 
KORA F3 2,532 191 (7.5%) 1,314 (51.9%) 1,133/863/536 53.62 (10.8) 55.77 (9.85) 53.44 (10.86) 2.33 
KORA F4 2,797 231(8.3%) 1,477 (52.8%) 1,228/1,045/524 54.90 (12.85) 54.15 (12.75) 54.97 (12.85) -0.82 
NAG-FIN 1,718 97 (5.6%) 782 (45.5%) 204/804/710 55.89 (7.63) 59.72 (9.07) 55.67 (7.48) 4.05 
NFBC1966 4,843 434 (9.0%) 2,516 (52.0%) 2,463/590/1,790 31 (0.2) 31 (0.2) 31 (0.2) 0 
NTR 7,529 906 (12.0%) 4,688 (62.3%) 3,734/2,213/1,582 42.50 (15.29) 41.51 (14.80) 42.64 (15.35) -1.13 
QIMR 315 149 (47.3%) 161 (51.1%) NA 20.94 (5.48) 20.60 (5.40) 21.25 (5.56) -0.65 
TwinGene 597 50 (8.4%) 597 (100%) 358/239* 71.72 (5.89) 71.69 (7.56) 71.73 (5.73) -0.04 
TwinsUK 4,243 531(12.5%) 3,869 (91.2%) 3,003/784/456 51.07 (13.39) 49.09 (14.20) 51.37 (13.25) -2.28 
total 31,029 2,834 (9.1%) 18,724 (60.3%) -0.27# 
*for TwinGene the numbers correspond to current smoking no/yes. #mean age difference between cases and controls, weighted by total sample size. 
  
Table 3: Study characteristics of studies in lung function indices analysis 
Study FITSA KORA Age KORA F3 KORA F4 NFBC1966 TwinFat TwinsUK 
Sample size 386 905 875 1,291 4,984  219  3,935 
number of women 386 (100%) 451 (49.8%) 458 (52.3%) 691 (53.5%) 2,594 (52.0%) 101 (46.1%)  3,687  (93.7%) 
Age [years] mean (sd) 68.45 (3.38) 75.67 (6.34) 44.45 (8.93) 51.62 (5.73) 31 (0.2) 27.60 (1.98) 51.17 (13.12) 
FEV1 [l] mean (sd) 2.20 (0.49) 2.49 (0.72) 3.56 (0.82) 3.34 (0.82) 3.95 (0.79) 4.03 (0.84) 2.74 (0.66) 
FVC [l] mean (sd) 2.82 (0.59) 3.36 (0.93) 4.3 (1.02) 4.30 (1.01) 4.72 (0.99) 4.74 (1.12)* 3.41 (0.73) 
FEV1/FVC mean [%] (sd) 78.19 (8.29) 74.32 (8.42) 83.09 (7.08) 77.65 (6.16) 84.11 (6.43) 84.98 (6.07)* 80.42 (8.47) 
zFEV1 mean (sd)  0.19 (1.34)  0.35 (1.17)  0.17 (1.06)  0.21 (1.16)  0.21 (1.01)  -0.03 (1.09) -0.09 (1.13) 
zFVC mean (sd)  0.13 (1.19)  0.47 (1.01)  -0.06 (0.98)  0.33 (0.97)  0.11 (0.95)  -0.29 (1.04)* -0.09 (0.98) 
zFEV1/FVC mean (sd)  -0.54 (1.13)  -0.26 (0.97)  0.42 (1.13)  -0.28 (0.89)  0.15 (1.13)  0.20 (0.96)* -0.02 (1.12)  
Smoking status 
never/former/current 
333/31/21 510/351/44 377/260/238 496/496/299 2,479/592/1,913 110/54/55 2,760/743/432 
*In TwinFat the analysis of FVC and FEV1/FVC is based on a subsample of n=124 subjects. 
